Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?

Cash payments and other arrangements between patent holders and their competitors in exchange for a delayed market entry interfere with free-market principles and keep product prices at a premium, which affects payers, governments, healthcare providers and especially patients.